The 15 references in paper S. Krasovsky A., I. Baranova A., E. Amelina L., N. Demin V., V. Samoilenko A., С. Красовский А., И. Баранова А., Е. Амелина Л., Н. Демин В., В. Самойленко А. (2014) “Оценка эффективности и безопасности алендроната в сочетании с холекальциферолом и кальцием в лечении взрослых больных муковисцидозом с низкой костной массой // Efficacy and safety of combined treatment with alendronate, cholecalciferol and calcium in adult cystic fibrosis patients with low bone mass” / spz:neicon:pulmonology:y:2012:i:2:p:71-77

1
Cystic Fibrosis Foundation. Patient registry 2009 annual report, Cystic Fibrosis Foundation. Bethesda, Md.; 2011. 55.
(check this in PDF content)
2
Лесняк О.М., Беневоленской Л.И.(ред.). Остеопороз. Диагностика, профилактика и лечение. 2-е изд. М.: ГЭОТАР-Медиа; 2009.
(check this in PDF content)
3
Aris R.M., Merkel P.A., Bachrach L.K. et al.Consensus statement: Guide to bone health and disease in cystic fibrosis. J. Clin. Endocrinol. 2005; 90 (3): 1888–1896.
(check this in PDF content)
4
Капустина Т.Ю., Капранов Н.И. Состояние минеральной плотности костной ткани у пациентов с муковисцидозом. Педиатрия 2008; 87 (5): 36–41.
(check this in PDF content)
5
Капустина Т.Ю., Федорова В.С., Воронкова А.Ю. и др. Снижение минеральной плотности костной ткани у пациентов с муковисцидозом: частота, факторы риска, подходы к терапии. В кн.: Муковисцидоз у детей и взрослых. Сборник статей и тезисов. Ярославль; 2007.
(check this in PDF content)
6
Соболенкова В.С.Системный анализ в ранней диагностике и лечении остеопенического синдрома при муковисцидозе: Автореф. дис. ... канд. мед. наук. Тула; 2009.
(check this in PDF content)
7
Aris R.M., Lester G.E., Renner J.B. et al.Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am. J. Respir. Crit. Care Med. 2000; 162 (3, Pt 1): 941–946.
(check this in PDF content)
8
Aris R.M., Lester G.E., Caminiti M. et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am. J. Resir. Crit. Care Med. 2004; 169 (1): 77–82.
(check this in PDF content)
9
Boyle M.P., Lechtzin N., Watts S.Zoledronate therapy for decreased bone density in adults with cystic fibrosis [abstract]. Pediatr. Pulm. 2005; 40 (S28): 353.
(check this in PDF content)
10
Chapman I., Greville H., Ebeling P.R. et al.Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin. Endocrinol. 2009; 70: 838–846.
(check this in PDF content)
11
Haworth C.S., Selby P.L., Adams J.E. et al. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis. Thorax 2001; 56 (4): 314–316.
(check this in PDF content)
12
Papaioannou A., Kennedy C.C., Freitag A. et al. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS Trial). Chest 2008; 134: 794–800.
(check this in PDF content)
13
Conway S.P., Oldroyd B., Morton A. et al. Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax 2004; 59 (8): 699–703.
(check this in PDF content)
14
Conwell L.S., Chang A.B.Bisphosphonates for osteoporosis in people with cystic fibrosis. (Review). Cochrane Library 2010, Issue 6.
(check this in PDF content)
15
Bertoldo F., Pancheri S., Zenari S. et al. Serum 25-Hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion. J. Bone Miner. Res. 2010: 25 (3): 447–454. Информация об авторах
(check this in PDF content)